Press release
Actinic Keratosis Market is Projected to Grow by 2036 Owing to the Rising Disease Burden and Emerging Novel Therapies | DelveInsight
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Actinic Keratosis Market Insight, Epidemiology, and Market Forecast-2036." This comprehensive report provides an in-depth understanding of Actinic Keratosis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Actinic Keratosis Market
*
The market size for Actinic Keratosis in the 7MM is expected to increase significantly by 2036.
*
According to the American Academy of Dermatology Association (AAD) (2026), more than 40 million Americans are estimated to develop actinic keratoses each year.
*
According to the National Institute for Health and Care Excellence (NICE), over 23% of individuals in the UK aged 60 years and above have actinic keratosis.
*
According to secondary research, the crude prevalence of actinic keratosis in France is estimated at 4.0%, with slightly higher prevalence in men than in women.
*
According to secondary research, the standardized prevalence of actinic keratosis in Germany is 2.7%, increasing with age to 11.5% in individuals aged 60-70 years. Approximately 1.7 million cases are documented annually.
*
Actinic keratosis is more prevalent in men and older populations due to cumulative sun exposure, with an estimated prevalence of around 20% in the United States.
*
KLISYRI (tirbanibulin) by Almirall and AMELUZ (aminolevulinic acid hydrochloride) by Biofrontera are key marketed therapies for actinic keratosis.
*
The emerging Actinic Keratosis pipeline includes Tuvatexib (VDA-1102) by Vidac Pharma and RLS-1496 by Rubedo Life Sciences.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/actinic-keratosis-market [https://www.delveinsight.com/sample-request/actinic-keratosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]
Key Factors Driving the Actinic Keratosis Market
*
The increasing incidence of chronic ultraviolet (UV) radiation exposure and aging populations are contributing significantly to the rising prevalence of actinic keratosis globally. Actinic keratoses are premalignant intra-epithelial skin lesions associated with chronic sun exposure and may progress to cutaneous squamous cell carcinoma if left untreated.
*
Growing awareness regarding early diagnosis and preventive dermatologic care is supporting higher treatment rates and encouraging the use of lesion-directed and field-directed therapies. Management strategies such as cryotherapy, photodynamic therapy, topical agents, chemical peels, and laser resurfacing are increasingly being utilized to minimize disease progression risk.
*
Advances in topical therapies and photodynamic treatment approaches are improving patient adherence and outcomes by offering shorter treatment durations and improved tolerability. Additionally, the development of novel targeted therapies with innovative mechanisms of action is expected to reshape the future treatment landscape.
Actinic Keratosis Competitive Landscape
Several therapies are currently available and under development for the management of Actinic Keratosis. KLISYRI (tirbanibulin) is a microtubule inhibitor indicated for topical field treatment of actinic keratosis of the face or scalp and offers a convenient 5-day treatment regimen. AMELUZ (aminolevulinic acid hydrochloride) is a photosensitizing agent used in combination with photodynamic therapy for selective destruction of atypical keratinocytes.
The emerging pipeline includes Tuvatexib (VDA-1102), an investigational topical therapy designed to selectively target abnormal keratinocytes while sparing healthy tissue through modulation of Hexokinase-2 activity. RLS-1496 is being developed as a selective GPX4 modulator targeting pathological senescent cells associated with chronic dermatologic conditions.
Discover more about therapies set to grab major Actinic Keratosis market share @ Actinic Keratosis Treatment Landscape [https://www.delveinsight.com/sample-request/actinic-keratosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]
Recent Developments in the Actinic Keratosis Market
*
In February 2026, Vidac Pharma announced that the first patient had been successfully enrolled and dosed in its Phase IIb clinical study evaluating VDA-1102 for the treatment of highly proliferative lesions of actinic keratosis.
*
In September 2025, Vidac Pharma announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a new interventional study focused on advanced actinic keratosis lesions.
*
In September 2025, Rubedo Life Sciences announced that the US FDA cleared the Investigational New Drug (IND) application for a Phase Ib/IIa clinical study of RLS-1496 in patients with actinic keratosis.
*
In June 2024, Almirall announced that the US FDA approved its supplemental New Drug Application (sNDA) to expand the treatment area for KLISYRI to up to 100 cm on the face or scalp.
*
In February 2024, the MHRA and the European Commission approved an extension of the marketing authorization for AMELUZ, allowing its use with artificial daylight photodynamic therapy for the treatment of actinic keratosis.
What is Actinic Keratosis?
Actinic keratosis, also known as solar keratosis or senile keratosis, is a premalignant skin condition caused by abnormal proliferation of keratinocytes due to chronic ultraviolet radiation exposure. These lesions typically appear as red, scaly papules or plaques on sun-exposed areas of the skin and may vary in size, texture, and pigmentation.
Although progression of a single lesion to cutaneous squamous cell carcinoma is relatively uncommon, the risk increases in patients with multiple lesions. Early detection, treatment, and long-term monitoring are important components of disease management.
Actinic Keratosis Epidemiology Segmentation
The Actinic Keratosis epidemiology section provides insights into the historical and current Actinic Keratosis patient pool and forecasted trends for the seven major markets. The Actinic Keratosis market report proffers epidemiological analysis for the study period 2022-2036 segmented into:
*
Total Incident Cases of Actinic Keratosis in the 7MM
*
Total Prevalent Cases of Actinic Keratosis in the 7MM
*
Total Diagnosed Prevalent Cases of Actinic Keratosis in the 7MM
*
Gender-specific Cases of Actinic Keratosis in the 7MM
*
Age-specific Cases of Actinic Keratosis in the 7MM
*
Total Treated Cases of Actinic Keratosis in the 7MM
Scope of the Actinic Keratosis Market Report
*
Therapeutic Assessment: Actinic Keratosis current marketed and emerging therapies
*
Actinic Keratosis Market Dynamics: Key Market Forecast Assumptions of Emerging Actinic Keratosis Drugs and Market Outlook
*
Key Companies: Almirall, Biofrontera, Vidac Pharma, Rubedo Life Sciences, and others
*
Key Therapies: KLISYRI (tirbanibulin), AMELUZ (aminolevulinic acid hydrochloride), Tuvatexib (VDA-1102), RLS-1496, and others
*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
*
Unmet Needs, KOL's views, Analyst's views, Actinic Keratosis Market Access and Reimbursement
To know more about Actinic Keratosis companies working in the treatment market, visit @ Actinic Keratosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/actinic-keratosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]
Table of Contents
*
Actinic Keratosis Market Overview at a Glance
*
Executive Summary
*
Key Events
*
Epidemiology and Market Methodology
*
Disease Background and Overview
*
Treatment and Management
*
Epidemiology and Patient Population
*
Marketed Drugs
*
Emerging Drugs
*
Actinic Keratosis Market Analysis
*
Key Opinion Leaders' Views
*
Unmet Needs
*
SWOT Analysis
*
Market Access and Reimbursement
*
Appendix
*
DelveInsight Capabilities
*
Disclaimer
*
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=actinic-keratosis-market-is-projected-to-grow-by-2036-owing-to-the-rising-disease-burden-and-emerging-novel-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Actinic Keratosis Market is Projected to Grow by 2036 Owing to the Rising Disease Burden and Emerging Novel Therapies | DelveInsight here
News-ID: 4539052 • Views: …
More Releases from ABNewswire
Diabetic Neuropathic Pain Market is Projected to Grow Significantly by 2034 Owin …
The market dynamics for Diabetic Neuropathic Pain are witnessing steady growth driven by the rising prevalence of diabetes, increasing burden of neuropathic complications, growing demand for effective symptomatic therapies, and advancements in pain management approaches. Additionally, the launch of emerging therapies such as Suzetrigine (Vertex Pharmaceuticals), Pilavapadin/LX9211 (Lexicon Pharmaceuticals), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Diabetic…
EGFR Inhibitors-induced Skin Disorders Market is Projected to Grow by 2036 Owing …
The market dynamics for EGFR Inhibitors-induced Skin Disorders are witnessing significant growth driven by the increasing use of EGFR inhibitors across multiple cancer indications, rising incidence of dermatologic toxicities associated with anti-EGFR therapies, and growing demand for effective supportive care management strategies. Additionally, the launch of emerging therapies such as LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics), ATR-04 (Azitra), and others will further fuel the market.
DelveInsight, a leading market research firm,…
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Ac …
The Key Gene and Cell Therapies Targeting CNS Disorders Companies in the market include - In8bio Inc., Brainstorm Cell Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Atara Biotherapeutics, Neuroplast, UniQure Biopharma, Asklepios Biopharmaceutical, Inc., Lexeo Therapeutics, Partner Therapeutics, Inc., Hoffmann-La Roche, Novartis, Freeline Therapeutics, Passage Bio, Inc., Black Diamond Therapeutics, Inc., and others.
DelveInsight's "Gene and Cell Therapies Targeting CNS Disorders Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of…
Chronic Wounds Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 3+ key companies continuously working towards developing 3+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Actinic
Actinic Keratosis Market Emerging Trends and Growth Prospects 2034
Introduction
Actinic keratosis (AK), also known as solar keratosis, is one of the most common precancerous skin conditions caused by long-term ultraviolet (UV) radiation exposure. It primarily affects older adults with fair skin and is considered a precursor to squamous cell carcinoma, making early detection and treatment critical. With rising awareness of skin cancer prevention, growing dermatology consultations, and expanding therapeutic innovations, the global actinic keratosis market is experiencing significant growth.
Over…
Actinic Keratosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Actinic Keratosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Actinic Keratosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including…
Global Actinic Keratosis Market Report Forecast to 2027
A rough, scaly area on the skin called an actinic keratosis Market develops after years of sun exposure. It commonly appears on the cheeks, lips, ears, forearms, scalp, neck, and backs of the hands. An actinic keratosis, also known as a sun keratosis, develops slowly and generally appears in persons over the age of 40. By limiting your sun exposure and protecting your skin from ultraviolet (UV) radiation, you…
Actinic Keratosis Market Insight, Epidemiology and Market Forecast -2026
The report studies the global Actinic Keratosis Market with many aspects of the industry like the market size, market status, market trends, and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. The report offers valuable insight into the Actinic Keratosis Market progress and approaches related to the market with an analysis of each region. The report goes on to…
Actinic Keratosis Treatment Market Growing Trends and Demands Analysis
The Global Actinic Keratosis Treatment Market is projected to increase at a compound annual growth rate of over 4% between 2018 and 2027. With the increased prevalence of actinic keratosis, demand for its therapeutic medications have also sprung upwards. Actinic keratosis remains an extremely common condition and its existence can be traced all over the world, however people living in countries with thinner ozone layer cover are more prone to…
United States Actinic Keratosis Treatment Market Report 2016
MarketResearchReports.biz has recently announced the addition of a market study “ United States Actinic Keratosis Treatment Market Report 2016 ”, is a comparative analysis of the global market.
Notes:
Sales, means the sales volume of Actinic Keratosis Treatment
Revenue, means the sales value of Actinic Keratosis Treatment
This report studies sales (consumption) of Actinic Keratosis Treatment in United States market, focuses on the top players, with sales, price, revenue and market…
